1. Home
  2. KRNY vs TECX Comparison

KRNY vs TECX Comparison

Compare KRNY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$9.54

Market Cap

526.7M

Sector

Finance

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$32.76

Market Cap

549.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
TECX
Founded
1884
2019
Country
United States
United States
Employees
N/A
60
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
526.7M
549.5M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KRNY
TECX
Price
$9.54
$32.76
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$9.25
$75.20
AVG Volume (30 Days)
723.6K
184.8K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
5.45%
N/A
EPS Growth
130.22
N/A
EPS
0.46
N/A
Revenue
$2,580,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$17.52
N/A
P/E Ratio
$20.75
N/A
Revenue Growth
36.00
N/A
52 Week Low
$5.76
$14.39
52 Week High
$9.76
$39.53

Technical Indicators

Market Signals
Indicator
KRNY
TECX
Relative Strength Index (RSI) 63.12 49.93
Support Level $9.05 $27.31
Resistance Level $9.66 $35.99
Average True Range (ATR) 0.21 2.74
MACD -0.02 -0.46
Stochastic Oscillator 71.13 24.39

Price Performance

Historical Comparison
KRNY
TECX

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: